Flow Chart: Schedule of Study Events

	Pre-Treatment Period	Treatment Period			Observation Period					
Activity	**Visit 1 (Weeks -12 to 0)**	**Visit 2 Week 0 (Day 0)**	**Visit 3 Week 3**	**Visit 4 Week 6**	**Visit 5 Week 10**	**Visit 6 Week 14**	**Visit 7 Week 18**	**Visit 8 Week 22**	**Visit 9 Week 26**	**Visit 10 2-4 weeks Post-LEEP**
Inclusion/Exclusion criteria satisfied	X									
Informed Consent signed	X									
Confirm CIN II/III by colposcopy[a]	X									
Confirm Medical History	X									
Complete Physical Examination	X								X	
Symptom-directed physical examination[b]		X	X	X	X					
Vital Signs	X	X[c]	X[c]	X[c]	X					
Hematology, chemistry, urinalysis	X									
HBV and HCV testing	X							X	X	X
Pregnancy Test (HCG in urine)	X	X	X	X						
Pelvic and colposcopic examination	X	X[d]	X	X	X	X	X	X	X	
Pap test cytology	X			X	X		X		X	
HPV testing (presence/absence)	X[e]			X	X		X		X	
HPV typing (by PCR)	X			X	X		X		X	
T4 and TSH testing	X				X				X	
Immunology blood samples (drawn before dosing at Weeks 0, 3, and 6)		X	X	X	X	X	X	X	X	
ZYC101a Injection (7-day window)		X	X	X						
Local tolerability assessment		X[f]	X[f]	X[f]	X					
Adverse event monitoring		X	X	X	X	X	X	X	X	
Concomitant medications review	X	X	X	X	X	X	X	X	X	
LEEP or equivalent procedure; histopathology on tissue samples				X[g]	X[g]	X[g]	X[g]	X[g]	X[h]	
Pharmacoeconomic data collection	X									X[i]

a. Confirmation of CIN II/III by colposcopy occurred between the time of biopsy and the first injection of ZYC101a, and did not exceed 12 weeks.
b Physical examination was directed to any areas of complaints or findings.
c Vital signs were taken before dosing and at 15, 30, and 60 minutes after dosing.
d Colposcopic exam could be waived at Visit 2, if it occurred within 4 weeks of Visit 1.
e HPV typing at Visit 1 occurred within 12 weeks of diagnosis of CIN II/III.
f Local tolerability was re-evaluated at 24 hours after dosing.
g LEEP or cold knife cone was performed on progressive lesions. Safety assessments were performed for 6 months from the time of the first injection of study drug.
h LEEP or cold knife cone was performed on all lesions at 6±1 months after the first injection of study drug. Safety assessments were performed before the LEEP.
I Pharmacoeconomic data were collected 2 or 4 weeks after the LEEP was performed, even if performed early.

Fig. 1


IFN-Gamma SFC/2.5X10E5 CD8+ Cells
Study Entry
Week 14
1602
1014
1809
1813
0100
0106
0211
0106
#1 #2 #3 #4 #5 #6 #7 #8 #9
#1 LLMGTLGTV:16
#2 LFLNTLSFV:18
#3 LLLGTLNTV:6/11
#4 KLPQLCTEL:16
#5 KLPDLCTEL:18
#6 SIDQLCKTF:11
#7 TIDQLCKTF:6
#8 NLLIRCLRC:18
#9 KVLIRCYLC:11

Fig. 2


Change in Tumor Size in TC-1 #6
versus
101a+electro:
* p=0.001
** p=0.0006
ZYC101a
ZYC900
naïve
ZYC101a+electro
ZYC900+electro
naïve+electro
Tumor Area (mme2)
180.0
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
Day 3
Day 7
Day 12
Day 17
Date of Measurment

Fig. 3